David versus goliath: ACE2-Fc receptor traps as potential SARS-CoV-2 inhibitors

References

• Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382(8):727–11. doi:10.1056/NEJMoa2001017.
   PubMed Web of Science ®Google Scholar
• Wang C, Horby PW, Hayden FG, Gao GF. A novel coronavirus outbreak of global health concern. Lancet. 2020;395:470–73. doi:10.1016/S0140-6736(20)30185-9.
   PubMed Web of Science ®Google Scholar
• Luan J, Lu Y, Jin X, Zhang L. Spike protein recognition of mammalian ACE2 predicts the host range and an optimized ACE2 for SARS-CoV-2 infection. Biochem Biophys Res Commun. 2020;526:165–69. doi:10.1016/j.bbrc.2020.03.047.
   PubMed Web of Science ®Google Scholar
• Tai W, He L, Zhang X, Pu J, Voronin D, Jiang S, Zhou Y, Du L. Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine. Cell Mol Immunol. 2020;17:613–20. doi:10.1038/s41423-020-0400-4.
   PubMed Web of Science ®Google Scholar
• Hoffmann M, Kleine-Weber H, Schroeder S, Kruger N, Herrler T, Erichsen S, Schiergens TS, Herrler G, Wu NH, Nitsche A, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181:271–80 e8. doi:10.1016/j.cell.2020.02.052.
   PubMed Web of Science ®Google Scholar
• Donoghue M, Hsieh F, Baronas E, Godbout K, Gosselin M, Stagliano N, Donovan M, Woolf B, Robison K, Jeyaseelan R, et al. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res. 2000;87:E1–9. doi:10.1161/01.res.87.5.e1.
   PubMed Web of Science ®Google Scholar
• Turner AJ, Tipnis SR, Guy JL, Rice G, Hooper NM. ACEH/ACE2 is a novel mammalian metallocarboxypeptidase and a homologue of angiotensin-converting enzyme insensitive to ACE inhibitors. Can J Physiol Pharmacol. 2002;80:346–53. doi:10.1139/y02-021.
   PubMed Web of Science ®Google Scholar
• Li W, Moore MJ, Vasilieva N, Sui J, Wong SK, Berne MA, Somasundaran M, Sullivan JL, Luzuriaga K, Greenough TC, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 2003;426:450–54. doi:10.1038/nature02145.
   PubMed Web of Science ®Google Scholar
• Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh CL, Abiona O, Graham BS, McLellan JS. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020;367:1260–63. doi:10.1126/science.abb2507.
   PubMed Web of Science ®Google Scholar
• Hoffmann M, Hofmann-Winkler H, Pöhlmann S. Priming time: how cellular proteases arm coronavirus spike proteins. Activation of Viruses by Host Proteases. 2018:71–98. doi:10.1007/978-3-319-75474-1_4.
   Google Scholar
• Glowacka I, Bertram S, Muller MA, Allen P, Soilleux E, Pfefferle S, Steffen I, Tsegaye TS, He Y, Gnirss K, et al. Evidence that TMPRSS2 activates the severe acute respiratory syndrome coronavirus spike protein for membrane fusion and reduces viral control by the humoral immune response. J Virol. 2011;85:4122–34. doi:10.1128/JVI.02232-10.
   PubMed Web of Science ®Google Scholar
• Matsuyama S, Nagata N, Shirato K, Kawase M, Takeda M, Taguchi F. Efficient activation of the severe acute respiratory syndrome coronavirus spike protein by the transmembrane protease TMPRSS2. J Virol. 2010;84:12658–64. doi:10.1128/JVI.01542-10.
   PubMed Web of Science ®Google Scholar
• Shulla A, Heald-Sargent T, Subramanya G, Zhao J, Perlman S, Gallagher T. A transmembrane serine protease is linked to the severe acute respiratory syndrome coronavirus receptor and activates virus entry. J Virol. 2011;85:873–82. doi:10.1128/JVI.02062-10.
   PubMed Web of Science ®Google Scholar
• Luft FC. ACE in the hole. J Mol Med (Berl). 2014;92:793–95. doi:10.1007/s00109-014-1172-z.
   PubMed Web of Science ®Google Scholar
• Gheblawi M, Wang K, Viveiros A, Nguyen Q, Zhong JC, Turner AJ, Raizada MK, Grant MB, Oudit GY. Angiotensin-Converting enzyme 2: SARS-CoV-2 receptor and regulator of the renin-angiotensin system: celebrating the 20th anniversary of the discovery of ACE2. Circ Res. 2020;126:1456–74. doi:10.1161/CIRCRESAHA.120.317015.
   PubMed Web of Science ®Google Scholar
• Sama IE, Ravera A, Santema BT, van Goor H, Ter Maaten JM, Cleland JGF, Rienstra M, Friedrich AW, Samani NJ, Ng LL, et al. Circulating plasma concentrations of angiotensin-converting enzyme 2 in men and women with heart failure and effects of renin-angiotensin-aldosterone inhibitors. Eur Heart J. 2020;41:1810–17. doi:10.1093/eurheartj/ehaa373.
   PubMed Web of Science ®Google Scholar
• Santos RA, Simoes E, Silva AC, Maric C, Silva DM, Machado RP, de Buhr I, Heringer-Walther S, Pinheiro SV, Lopes MT, et al. Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc Natl Acad Sci U S A. 2003;100:8258–63. doi:10.1073/pnas.1432869100.
   PubMed Web of Science ®Google Scholar
• Haschke M, Schuster M, Poglitsch M, Loibner H, Salzberg M, Bruggisser M, Penninger J, Krahenbuhl S. Pharmacokinetics and pharmacodynamics of recombinant human angiotensin-converting enzyme 2 in healthy human subjects. Clin Pharmacokinet. 2013;52:783–92. doi:10.1007/s40262-013-0072-7.
   PubMed Web of Science ®Google Scholar
• Kuba K, Imai Y, Rao S, Gao H, Guo F, Guan B, Huan Y, Yang P, Zhang Y, Deng W, et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat Med. 2005;11:875–79. doi:10.1038/nm1267.
   PubMed Web of Science ®Google Scholar
• Imai Y, Kuba K, Rao S, Huan Y, Guo F, Guan B, Yang P, Sarao R, Wada T, Leong-Poi H, et al. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature. 2005;436:112–16. doi:10.1038/nature03712.
   PubMed Web of Science ®Google Scholar
• Monteil V, Kwon H, Prado P, Hagelkruys A, Wimmer RA, Stahl M, Leopoldi A, Garreta E, Hurtado Del Pozo C, Prosper F, et al. Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2. Cell. 2020;181:905–13 e7. doi:10.1016/j.cell.2020.04.004.
   PubMed Web of Science ®Google Scholar
• Zoufaly A, Poglitsch M, Aberle JH, Hoepler W, Seitz T, Traugott M, Grieb A, Pawelka E, Laferl H, Wenisch C, et al. Human recombinant soluble ACE2 in severe COVID-19. Lancet Respir Med. 2020;8:1154–58. doi:10.1016/S2213-2600(20)30418-5.
   PubMed Web of Science ®Google Scholar
• Khan A, Benthin C, Zeno B, Albertson TE, Boyd J, Christie JD, Hall R, Poirier G, Ronco JJ, Tidswell M, et al. A pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in acute respiratory distress syndrome. Crit Care. 2017;21:234. doi:10.1186/s13054-017-1823-x.
   PubMed Web of Science ®Google Scholar
• Yan R, Zhang Y, Li Y, Xia L, Guo Y, Zhou Q. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science. 2020;367:1444–48. doi:10.1126/science.abb2762.
   PubMed Web of Science ®Google Scholar
• Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, Si HR, Zhu Y, Li B, Huang CL, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579:270–73. doi:10.1038/s41586-020-2012-7.
   PubMed Web of Science ®Google Scholar
• Gu H, Xie Z, Li T, Zhang S, Lai C, Zhu P, Wang K, Han L, Duan Y, Zhao Z, et al. Angiotensin-converting enzyme 2 inhibits lung injury induced by respiratory syncytial virus. Sci Rep. 2016;6:19840. doi:10.1038/srep19840.
   PubMed Web of Science ®Google Scholar
• Zou Z, Yan Y, Shu Y, Gao R, Sun Y, Li X, Ju X, Liang Z, Liu Q, Zhao Y, et al. Angiotensin-converting enzyme 2 protects from lethal avian influenza A H5N1 infections. Nat Commun. 2014;5:3594. doi:10.1038/ncomms4594.
   PubMed Web of Science ®Google Scholar
• van Dorp L, Richard D, Tan CCS, Shaw LP, Acman M, Balloux F. No evidence for increased transmissibility from recurrent mutations in SARS-CoV-2. Nat Commun. 2020;11:5986. doi:10.1038/s41467-020-19818-2.
   PubMed Web of Science ®Google Scholar
• Williams TC, Burgers WA. SARS-CoV-2 evolution and vaccines: cause for concern? Lancet Respir Med. 2021;9:333–35. doi:10.1016/S2213-2600(21)00075-8.
   PubMed Web of Science ®Google Scholar
• Xie X, Liu Y, Liu J, Zhang X, Zou J, Fontes-Garfias CR, Xia H, Swanson KA, Cutler M, Cooper D, et al. Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera. Nat Med. 2021;27:620–21. doi:10.1038/s41591-021-01270-4.
   PubMed Web of Science ®Google Scholar
• Chen RE, Zhang X, Case JB, Winkler ES, Liu Y, VanBlargan LA, Liu J, Errico JM, Xie X, Suryadevara N, et al. Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies. Nat Med. 2021;27:717–26. doi:10.1038/s41591-021-01294-w.
   PubMed Web of Science ®Google Scholar
• Starr TN, Greaney AJ, Addetia A, Hannon WW, Choudhary MC, Dingens AS, Li JZ, Bloom JD. Prospective mapping of viral mutations that escape antibodies used to treat COVID-19. Science. 2021;371:850–54. doi:10.1126/science.abf9302.
   PubMed Web of Science ®Google Scholar
• Weisblum Y, Schmidt F, Zhang F, DaSilva J, Poston D, Lorenzi JC, Muecksch F, Rutkowska M, Hoffmann HH, Michailidis E, et al. Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants. Elife. 2020;9. doi:10.7554/eLife.61312.
   PubMed Web of Science ®Google Scholar
• Kemp SA, Collier DA, Datir RP, Ferreira I, Gayed S, Jahun A, Hosmillo M, Rees-Spear C, Mlcochova P, Lumb IU, et al. SARS-CoV-2 evolution during treatment of chronic infection. Nature. 2021;592:277–82. doi:10.1038/s41586-021-03291-y.
   PubMed Web of Science ®Google Scholar
• Yuan M, Huang D, Lee CD, Wu NC, Jackson AM, Zhu X, Liu H, Peng L, van Gils MJ, Sanders RW, et al. Structural and functional ramifications of antigenic drift in recent SARS-CoV-2 variants. Science. 2021;373:818–23. doi:10.1126/science.abh1139.
   PubMed Web of Science ®Google Scholar
• Chan KK, Dorosky D, Sharma P, Abbasi SA, Dye JM, Kranz DM, Herbert AS, Procko E. Engineering human ACE2 to optimize binding to the spike protein of SARS coronavirus 2. Science. 2020;369:1261–65. doi:10.1126/science.abc0870.
   PubMed Web of Science ®Google Scholar
• Chan KK, Tan TJC, Narayanan KK, Procko E. An engineered decoy receptor for SARS-CoV-2 broadly binds protein S sequence variants. bioRxiv. 2020. doi:10.1101/2020.10.18.344622.
   Google Scholar
• Mehdipour AR, Hummer G. Dual nature of human ACE2 glycosylation in binding to SARS-CoV-2 spike. Proc Natl Acad Sci U S A. 2021:118. doi:10.1073/pnas.2100425118.
   Web of Science ®Google Scholar
• Casalino L, Gaieb Z, Goldsmith JA, Hjorth CK, Dommer AC, Harbison AM, Fogarty CA, Barros EP, Taylor BC, McLellan JS, et al. Beyond shielding: the roles of glycans in the SARS-CoV-2 spike protein. ACS Cent Sci. 2020;6:1722–34. doi:10.1021/acscentsci.0c01056.
   PubMed Web of Science ®Google Scholar
• Sztain T, Ahn SH, Bogetti AT, Casalino L, Goldsmith JA, Seitz E, McCool RS, Kearns FL, Acosta-Reyes F, Maji S, et al. A glycan gate controls opening of the SARS-CoV-2 spike protein. bioRxiv. 2021. doi:10.1101/2021.02.15.431212.
   Google Scholar
• Capraz T, Kienzl NF, Laurent E, Perthold JW, Foderl-Hobenreich E, Grunwald-Gruber C, Maresch D, Monteil V, Niederhofer J, Wirnsberger G, et al. Structure-guided glyco-engineering of ACE2 for improved potency as soluble SARS-CoV-2 decoy receptor. Elife. 2021;10. doi:10.7554/eLife.73641.
   PubMed Web of Science ®Google Scholar
• Wallentin L, Lindback J, Eriksson N, Hijazi Z, Eikelboom JW, Ezekowitz MD, Granger CB, Lopes RD, Yusuf S, Oldgren J, et al. Angiotensin-converting enzyme 2 (ACE2) levels in relation to risk factors for COVID-19 in two large cohorts of patients with atrial fibrillation. Eur Heart J. 2020;41:4037–46. doi:10.1093/eurheartj/ehaa697.
   PubMed Web of Science ®Google Scholar
• Sama IE, Voors AA, van Veldhuisen DJ. New data on soluble ACE2 in patients with atrial fibrillation reveal potential value for treatment of patients with COVID-19 and cardiovascular disease. Eur Heart J. 2020;41:4047–49. doi:10.1093/eurheartj/ehaa761.
   PubMed Web of Science ®Google Scholar
• Mehra MR, Desai SS, Kuy S, Henry TD, Patel AN. Cardiovascular disease, drug therapy, and Mortality in Covid-19. N Engl J Med. 2020;382:e102. doi:10.1056/NEJMoa2007621.
   PubMed Web of Science ®Google Scholar
• Guo J, Huang Z, Lin L, Lv J. Coronavirus Disease 2019 (COVID-19) and cardiovascular disease: a viewpoint on the potential influence of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers on onset and severity of severe acute respiratory syndrome coronavirus 2 Infection. J Am Heart Assoc. 2020;9:e016219. doi:10.1161/JAHA.120.016219.
   PubMed Web of Science ®Google Scholar
• Yasui F, Kohara M, Kitabatake M, Nishiwaki T, Fujii H, Tateno C, Yoneda M, Morita K, Matsushima K, Koyasu S, et al. Phagocytic cells contribute to the antibody-mediated elimination of pulmonary-infected SARS coronavirus. Virology. 2014;454-455:157–68. doi:10.1016/j.virol.2014.02.005.
   PubMed Web of Science ®Google Scholar
• Kruse RL. Therapeutic strategies in an outbreak scenario to treat the novel coronavirus originating in Wuhan, China. F1000Res. 2020;9:72. doi:10.12688/f1000research.22211.2.
   PubMedGoogle Scholar
• Bitonti AJ, Dumont JA, Low SC, Peters RT, Kropp KE, Palombella VJ, Stattel JM, Lu Y, Tan CA, Song JJ, et al. Pulmonary delivery of an erythropoietin Fc fusion protein in non-human primates through an immunoglobulin transport pathway. Proc Natl Acad Sci U S A. 2004;101:9763–68. doi:10.1073/pnas.0403235101.
   PubMed Web of Science ®Google Scholar
• Strohl WR. Fusion proteins for half-life extension of biologics as a strategy to make biobetters. BioDrugs. 2015;29:215–39. doi:10.1007/s40259-015-0133-6.
   PubMed Web of Science ®Google Scholar
• Unverdorben F, Richter F, Hutt M, Seifert O, Malinge P, Fischer N, Kontermann RE. Pharmacokinetic properties of IgG and various Fc fusion proteins in mice. MAbs. 2016;8:120–28. doi:10.1080/19420862.2015.1113360.
   PubMed Web of Science ®Google Scholar
• Czajkowsky DM, Hu J, Shao Z, Pleass RJ. Fc-fusion proteins: new developments and future perspectives. EMBO Mol Med. 2012;4:1015–28. doi:10.1002/emmm.201201379.
   PubMed Web of Science ®Google Scholar
• Sockolosky JT, Szoka FC. The neonatal Fc receptor, FcRn, as a target for drug delivery and therapy. Adv Drug Deliv Rev. 2015;91:109–24. doi:10.1016/j.addr.2015.02.005.
   PubMed Web of Science ®Google Scholar
• Latvala S, Jacobsen B, Otteneder MB, Herrmann A, Kronenberg S. Distribution of FcRn Across Species and Tissues. J Histochem Cytochem. 2017;65:321–33. doi:10.1369/0022155417705095.
   PubMed Web of Science ®Google Scholar
• Tzaban S, Massol RH, Yen E, Hamman W, Frank SR, Lapierre LA, Hansen SH, Goldenring JR, Blumberg RS, Lencer WI. The recycling and transcytotic pathways for IgG transport by FcRn are distinct and display an inherent polarity. J Cell Biol. 2009;185:673–84. doi:10.1083/jcb.200809122.
   PubMed Web of Science ®Google Scholar
• Kariolis MS, Miao YR, Jones DS 2nd, Kapur S, Mathews II, Giaccia AJ, Cochran JR. An engineered Axl ‘decoy receptor’ effectively silences the Gas6-Axl signaling axis. Nat Chem Biol. 2014;10:977–83. doi:10.1038/nchembio.1636.
   PubMed Web of Science ®Google Scholar
• Huang C. Receptor-Fc fusion therapeutics, traps, and MIMETIBODY technology. Curr Opin Biotechnol. 2009;20:692–99. doi:10.1016/j.copbio.2009.10.010.
   PubMed Web of Science ®Google Scholar
• Wycoff K, Maclean J, Belle A, Yu L, Tran Y, Roy C, Hayden F. Anti-infective immunoadhesins from plants. Plant Biotechnol J. 2015;13:1078–93. doi:10.1111/pbi.12441.
   PubMed Web of Science ®Google Scholar
• Duivelshof BL, Murisier A, Camperi J, Fekete S, Beck A, Guillarme D, D’Atri V. Therapeutic Fc-fusion proteins: current analytical strategies. J Sep Sci. 2021;44:35–62. doi:10.1002/jssc.202000765.
   PubMed Web of Science ®Google Scholar
• Shearer WT, Israel RJ, Starr S, Fletcher CV, Wara D, Rathore M, Church J, DeVille J, Fenton T, Graham B, et al. Recombinant CD4-IgG2 in human immunodeficiency virus type 1-infected children: phase 1/2 study. The Pediatric AIDS Clinical Trials Group Protocol 351 Study Team. J Infect Dis. 2000;182:1774–79. doi:10.1086/317622.
   Google Scholar
• Chi X, Yan R, Zhang J, Zhang G, Zhang Y, Hao M, Zhang Z, Fan P, Dong Y, Yang Y, et al. A neutralizing human antibody binds to the N-terminal domain of the spike protein of SARS-CoV-2. Science. 2020;369:650–55. doi:10.1126/science.abc6952.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Zeng E, Zhang L, Wang W, Jin Y, Sun J, Huang S, Yin W, Dai J, Zhuang Z, et al. Potent prophylactic and therapeutic efficacy of recombinant human ACE2-Fc against SARS-CoV-2 infection in vivo. Cell Discov. 2021;7:65. doi:10.1038/s41421-021-00302-0.
   PubMed Web of Science ®Google Scholar
• Liu P, Xie X, Gao L, Jin J. Designed variants of ACE2-Fc that decouple anti-SARS-CoV-2 activities from unwanted cardiovascular effects. Int J Biol Macromol. 2020;165:1626–33. doi:10.1016/j.ijbiomac.2020.10.120.
   PubMed Web of Science ®Google Scholar
• Lei C, Qian K, Li T, Zhang S, Fu W, Ding M, Hu S. Neutralization of SARS-CoV-2 spike pseudotyped virus by recombinant ACE2-Ig. Nat Commun. 2020;11:2070. doi:10.1038/s41467-020-16048-4.
   PubMed Web of Science ®Google Scholar
• Iwanaga N, Cooper L, Rong L, Maness NJ, Beddingfield B, Qin Z, Crabtree J, Tripp RA, Yang H, Blair R, et al. ACE2-IgG1 fusions with improved in vitro and in vivo activity against SARS-CoV-2. iScience. 2022;25:103670. doi:10.1016/j.isci.2021.103670.
   PubMed Web of Science ®Google Scholar
• Vickers C, Hales P, Kaushik V, Dick L, Gavin J, Tang J, Godbout K, Parsons T, Baronas E, Hsieh F, et al. Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. J Biol Chem. 2002;277:14838–43. doi:10.1074/jbc.M200581200.
   PubMed Web of Science ®Google Scholar
• Glasgow A, Glasgow J, Limonta D, Solomon P, Lui I, Zhang Y, Nix MA, Rettko NJ, Zha S, Yamin R, et al. Engineered ACE2 receptor traps potently neutralize SARS-CoV-2. Proc Natl Acad Sci U S A. 2020;117:28046–55. doi:10.1073/pnas.2016093117.
   PubMed Web of Science ®Google Scholar
• Fridrich S, Karmilin K, Stocker W. Handling metalloproteinases. Curr Protoc Protein Sci. 2016;83(21). doi:10.1002/0471140864.ps2116s83.
   PubMedGoogle Scholar
• Namuswe F, Berg JM. Secondary interactions involving zinc-bound ligands: roles in structural stabilization and macromolecular interactions. J Inorg Biochem. 2012;111:146–49. doi:10.1016/j.jinorgbio.2011.10.018.
   PubMed Web of Science ®Google Scholar
• McCall KA, Huang C, Fierke CA. Function and mechanism of zinc metalloenzymes. J Nutr. 2000;130:1437S–46S. doi:10.1093/jn/130.5.1437S.
   PubMed Web of Science ®Google Scholar
• Miao X, Luo Y, Huang X, Lee SMY, Yuan Z, Tang Y, Chen L, Wang C, Wu F, Xu Y, et al. A novel biparatopic hybrid antibody-ACE2 fusion that blocks SARS-CoV-2 infection: implications for therapy. MAbs. 2020;12:1804241. doi:10.1080/19420862.2020.1804241.
   PubMed Web of Science ®Google Scholar
• Xu C, Wang Y, Liu C, Zhang C, Han W, Hong X, Wang Y, Hong Q, Wang S, Zhao Q, et al. Conformational dynamics of SARS-CoV-2 trimeric spike glycoprotein in complex with receptor ACE2 revealed by cryo-EM. Sci Adv. 2021;7. doi:10.1126/sciadv.abe5575.
   Web of Science ®Google Scholar
• Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler DS. Function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell. 2020;181:281–92 e6. doi:10.1016/j.cell.2020.02.058.
   PubMed Web of Science ®Google Scholar
• Lan J, Ge J, Yu J, Shan S, Zhou H, Fan S, Zhang Q, Shi X, Wang Q, Zhang L, et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature. 2020;581:215–20. doi:10.1038/s41586-020-2180-5.
   PubMed Web of Science ®Google Scholar
• Bertoglio F, Meier D, Langreder N, Steinke S, Rand U, Simonelli L, Heine PA, Ballmann R, Schneider KT, Roth KDR, et al. SARS-CoV-2 neutralizing human recombinant antibodies selected from pre-pandemic healthy donors binding at RBD-ACE2 interface. Nat Commun. 2021;12:1577. doi:10.1038/s41467-021-21609-2.
   PubMed Web of Science ®Google Scholar
• Bracken CJ, Lim SA, Solomon P, Rettko NJ, Nguyen DP, Zha BS, Schaefer K, Byrnes JR, Zhou J, Lui I, et al. Bi-paratopic and multivalent VH domains block ACE2 binding and neutralize SARS-CoV-2. Nat Chem Biol. 2021;17:113–21. doi:10.1038/s41589-020-00679-1.
   PubMed Web of Science ®Google Scholar
• Hwang YC, Lu RM, Su SC, Chiang PY, Ko SH, Ke FY, Liang KH, Hsieh TY, Wu HC. Monoclonal antibodies for COVID-19 therapy and SARS-CoV-2 detection. J Biomed Sci. 2022;29:1. doi:10.1186/s12929-021-00784-w.
   PubMed Web of Science ®Google Scholar
• Shi R, Shan C, Duan X, Chen Z, Liu P, Song J, Song T, Bi X, Han C, Wu L, et al. A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2. Nature. 2020;584:120–24. doi:10.1038/s41586-020-2381-y.
   PubMed Web of Science ®Google Scholar
• Wu Y, Wang F, Shen C, Peng W, Li D, Zhao C, Li Z, Li S, Bi Y, Yang Y, et al. A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2. Science. 2020;368:1274–78. doi:10.1126/science.abc2241.
   PubMed Web of Science ®Google Scholar
• Wang Q, Zhang Y, Wu L, Niu S, Song C, Zhang Z, Lu G, Qiao C, Hu Y, Yuen KY, et al. Structural and functional basis of SARS-CoV-2 entry by using human ACE2. Cell. 2020;181:894–904 e9. doi:10.1016/j.cell.2020.03.045.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Perez D, Garcia-Ruiz E, Alcalde M. Saccharomyces cerevisiae in directed evolution: an efficient tool to improve enzymes. Bioeng Bugs. 2012;3:172–77. doi:10.4161/bbug.19544.
   PubMedGoogle Scholar
• Li Y, Wang H, Tang X, Fang S, Ma D, Du C, Wang Y, Pan H, Yao W, Zhang R, et al. SARS-CoV-2 and three related coronaviruses utilize multiple ACE2 orthologs and are potently blocked by an improved ACE2-Ig. J Virol. 2020;94. doi:10.1128/JVI.01283-20.
   Web of Science ®Google Scholar
• Guy JL, Jackson RM, Jensen HA, Hooper NM, Turner AJ. Identification of critical active-site residues in angiotensin-converting enzyme-2 (ACE2) by site-directed mutagenesis. FEBS J. 2005;272:3512–20. doi:10.1111/j.1742-4658.2005.04756.x.
   PubMed Web of Science ®Google Scholar
• Liu P, Xie X, Gao L, Jin J. His345 mutant of angiotensin-converting enzyme 2 (ACE2) remains enzymatically active against angiotensin II. Proc Natl Acad Sci U S A. 2021:118. doi:10.1073/pnas.2023648118.
   Web of Science ®Google Scholar
• Glasgow J, Glasgow A, Kortemme T, Wells JA , et al. Reply to Liu et al.: Specific mutations matter in specificity and catalysis in ACE2. Proc Natl Acad Sci U S A. 2021;118. doi:10.1073/pnas.2024450118.
   Web of Science ®Google Scholar
• Higuchi Y, Suzuki T, Arimori T, Ikemura N, Mihara E, Kirita Y, Ohgitani E, Mazda O, Motooka D, Nakamura S, et al. Engineered ACE2 receptor therapy overcomes mutational escape of SARS-CoV-2. Nat Commun. 2021;12:3802. doi:10.1038/s41467-021-24013-y.
   PubMed Web of Science ®Google Scholar
• Swiech K, de Freitas Mc, Covas DT, Picanco-Castro V. Recombinant glycoprotein production in human cell lines. Methods Mol Biol. 2015;1258:223–40. doi:10.1007/978-1-4939-2205-5_12.
   PubMedGoogle Scholar
• Gemmill TR, Trimble RB. Overview of N- and O-linked oligosaccharide structures found in various yeast species. Biochim Biophys Acta. 1999;1426:227–37. doi:10.1016/s0304-4165(98)00126-3.
   PubMed Web of Science ®Google Scholar
• Benton DJ, Wrobel AG, Xu P, Roustan C, Martin SR, Rosenthal PB, Skehel JJ, Gamblin SJ. Receptor binding and priming of the spike protein of SARS-CoV-2 for membrane fusion. Nature. 2020;588:327–30. doi:10.1038/s41586-020-2772-0.
   PubMed Web of Science ®Google Scholar
• Shimon A, Shani O, Diskin R. Structural basis for receptor selectivity by the whitewater arroyo mammarenavirus. J Mol Biol. 2017;429:2825–39. doi:10.1016/j.jmb.2017.07.011.
   PubMed Web of Science ®Google Scholar
• Wacharapluesadee S, Tan CW, Maneeorn P, Duengkae P, Zhu F, Joyjinda Y, Kaewpom T, Chia WN, Ampoot W, Lim BL, et al. Evidence for SARS-CoV-2 related coronaviruses circulating in bats and pangolins in Southeast Asia. Nat Commun. 2021;12:972. doi:10.1038/s41467-021-21240-1.
   PubMed Web of Science ®Google Scholar
• Cohen-Dvashi H, Weinstein J, Katz M, Eilon M, Mor Y, Shimon A, Strobelt R, Shemesh M, Fleishman SJ, Diskin R. Coronacept – a potent immunoadhesin against SARS-CoV-2. bioRxiv. 2020. doi:10.1101/2020.08.12.247940.
   Google Scholar
• Mou H, Quinlan BD, Peng H, Liu G, Guo Y, Peng S, Zhang L, Davis-Gardner ME, Gardner MR, Crynen G, et al. Mutations derived from horseshoe bat ACE2 orthologs enhance ACE2-Fc neutralization of SARS-CoV-2. PLoS Pathog. 2021;17:e1009501. doi:10.1371/journal.ppat.1009501.
   PubMed Web of Science ®Google Scholar
• Xiao K, Zhai J, Feng Y, Zhou N, Zhang X, Zou JJ, Li N, Guo Y, Li X, Shen X, et al. Isolation of SARS-CoV-2-related coronavirus from Malayan pangolins. Nature. 2020;583:286–89. doi:10.1038/s41586-020-2313-x.
   PubMed Web of Science ®Google Scholar
• Letko M, Marzi A, Munster V. Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses. Nat Microbiol. 2020;5:562–69. doi:10.1038/s41564-020-0688-y.
   PubMed Web of Science ®Google Scholar
• Mallapaty S. The search for animals harbouring coronavirus - and why it matters. Nature. 2021;591:26–28. doi:10.1038/d41586-021-00531-z.
   PubMed Web of Science ®Google Scholar
• Patterson EI, Elia G, Grassi A, Giordano A, Desario C, Medardo M, Smith SL, Anderson ER, Prince T, Patterson GT, et al. Evidence of exposure to SARS-CoV-2 in cats and dogs from households in Italy. bioRxiv. 2020. doi:10.1101/2020.07.21.214346.
   Google Scholar
• Sit THC, Brackman CJ, Ip SM, Tam KWS, Law PYT, Emw T, Vyt Y, Sims LD, Tsang DNC, Chu DKW, et al. Infection of dogs with SARS-CoV-2. Nature. 2020;586:776–78. doi:10.1038/s41586-020-2334-5.
   PubMed Web of Science ®Google Scholar
• Eroshenko N, Gill T, Keaveney MK, Church GM, Trevejo JM, Rajaniemi H. Implications of antibody-dependent enhancement of infection for SARS-CoV-2 countermeasures. Nat Biotechnol. 2020;38:789–91. doi:10.1038/s41587-020-0577-1.
   PubMed Web of Science ®Google Scholar
• Jafarzadeh A, Chauhan P, Saha B, Jafarzadeh S, Nemati M. Contribution of monocytes and macrophages to the local tissue inflammation and cytokine storm in COVID-19: lessons from SARS and MERS, and potential therapeutic interventions. Life Sci. 2020;257:118102. doi:10.1016/j.lfs.2020.118102.
   PubMed Web of Science ®Google Scholar
• Manickam C, Sugawara S, Reeves RK. Friends or foes? The knowns and unknowns of natural killer cell biology in COVID-19 and other coronaviruses in July 2020. PLoS Pathog. 2020;16:e1008820. doi:10.1371/journal.ppat.1008820.
   PubMed Web of Science ®Google Scholar
• de Taeye Sw, Bentlage AEH, Mebius MM, Meesters JI, Lissenberg-Thunnissen S, Falck D, Senard T, Salehi N, Wuhrer M, Schuurman J, et al. FcgammaR binding and ADCC Activity of human igg allotypes. Front Immunol. 2020;11:740. doi:10.3389/fimmu.2020.00740.
   PubMed Web of Science ®Google Scholar
• van Erp Ea, Luytjes W, Ferwerda G, van Kasteren PB, van Erp EA. Fc-Mediated antibody effector functions during respiratory syncytial virus infection and disease. Front Immunol. 2019;10:548. doi:10.3389/fimmu.2019.00548.
   PubMed Web of Science ®Google Scholar
• Svilenov HL, Sacherl J, Reiter A, Wolff LS, Cheng CC, Stern M, Grass V, Feuerherd M, Wachs FP, Simonavicius N, et al. Picomolar inhibition of SARS-CoV-2 variants of concern by an engineered ACE2-IgG4-Fc fusion protein. Antiviral Res. 2021;196:105197. doi:10.1016/j.antiviral.2021.105197.
   PubMed Web of Science ®Google Scholar
• Correia IR. Stability of IgG isotypes in serum. MAbs. 2010;2(3):221–32. doi:10.4161/mabs.2.3.11788.
   PubMed Web of Science ®Google Scholar
• Dumet C, Pottier J, Gouilleux-Gruart V, Watier H. Insights into the IgG heavy chain engineering patent landscape as applied to IgG4 antibody development. MAbs. 2019;11(8):1341–50. doi:10.1080/19420862.2019.1664365.
   PubMed Web of Science ®Google Scholar
• Aalberse RC, Schuurman J. IgG4 breaking the rules. Immunology. 2002;105(1):9–19. doi:10.1046/j.0019-2805.2001.01341.x.
   PubMed Web of Science ®Google Scholar
• Handlogten MW, Peng L, Christian EA, Xu W, Lin S, Venkat R, Dall’Acqua W, Ahuja S. Prevention of Fab-arm exchange and antibody reduction via stabilization of the IgG4 hinge region. MAbs. 2020;12:1779974. doi:10.1080/19420862.2020.1779974.
   PubMed Web of Science ®Google Scholar
• Silva JP, Vetterlein O, Jose J, Peters S, Kirby H. The S228P mutation prevents in vivo and in vitro IgG4 Fab-arm exchange as demonstrated using a combination of novel quantitative immunoassays and physiological matrix preparation. J Biol Chem. 2015;290:5462–69. doi:10.1074/jbc.M114.600973.
   PubMed Web of Science ®Google Scholar
• Ferrari M, Mekkaoui L, Ilca FT, Akbar Z, Bughda R, Lamb K, Ward K, Parekh F, Karattil R, Allen C, et al. Characterization of a Novel ACE2-Based therapeutic with enhanced rather than reduced activity against SARS-CoV-2 variants. J Virol. 2021;95:e0068521. doi:10.1128/JVI.00685-21.
   PubMed Web of Science ®Google Scholar
• Zhang H, Penninger JM, Li Y, Zhong N, Slutsky AS. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med. 2020;46:586–90. doi:10.1007/s00134-020-05985-9.
   PubMed Web of Science ®Google Scholar
• Tovey MG, Lallemand C. Immunogenicity and other problems associated with the use of biopharmaceuticals. Ther Adv Drug Saf. 2011;2:113–28. doi:10.1177/2042098611406318.
   PubMedGoogle Scholar
• Alfaleh MA, Alsaab HO, Mahmoud AB, Alkayyal AA, Jones ML, Mahler SM, Hashem AM. Phage display derived monoclonal antibodies: from bench to bedside. Front Immunol. 2020;11:1986. doi:10.3389/fimmu.2020.01986.
   PubMed Web of Science ®Google Scholar
• Salazar-Fontana LI, Desai DD, Khan TA, Pillutla RC, Prior S, Ramakrishnan R, Schneider J, Joseph A. Approaches to mitigate the unwanted immunogenicity of therapeutic proteins during drug development. AAPS J. 2017;19:377–85. doi:10.1208/s12248-016-0030-z.
   PubMed Web of Science ®Google Scholar